CSPC PHARMA(01093.HK): Receives USD10‑Million Milestone Payment from AstraZeneca
NewTimeSpace News: CSPC Pharma (01093.HK) released a voluntary announcement on 5 August 2026. The Group has received a USD10‑million milestone payment from AstraZeneca for exercising the licensing option for one pre‑clinical candidate compound (PCC) project in accordance with the agreement terms, which indicates that relevant R&D work under the agreement is advancing steadily as planned.
The two parties entered into the strategic R&D cooperation agreement on 13 June 2025. The Group agreed to discover PCCs with multi‑disease therapeutic potential for multiple targets selected by AstraZeneca, including one pre‑clinical small‑molecule oral therapy for immune diseases.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- CSPC PHARMA(01093.HK): Joint Venture Established with AstraZeneca, Holding 51% Stake to Co‑Build Biologics Manufacturing Base
- CSPC PHARMA(01093.HK): NDA for Neoadjuvant Therapy of Anitumab Combined with HB1801 in HER2‑positive Breast Cancer Accepted and Granted Priority Review
- CSPC PHARMA(01093.HK): Phase Ib/II Clinical Trial of SYS6090 Injection for Colorectal Cancer Initiated at First Study Centre in China
- CSPC Pharmaceutical (01093.HK): SYH2062 Hypertension Phase II Trial Initiated at First China Site; CRB-701 FDA Cleared for Pivotal OPSCC Trial
- CSPC Pharmaceutical (01093.HK): NDA for Sirolimus Albumin-Bound Injection Accepted by NMPA with Breakthrough Therapy and Priority Review Status
